Introduction
Materials and methods
Study design
Data source
Statistical analysis
Results
Oncotype DX group | Controls | |
---|---|---|
N = 282 |
N = 669 | |
Age | ||
Median (range), years | 61.5 (36–87) | 59.0 (24–93) |
Age categorya, N (%) | ||
<40 years | 6 (2.1) | 34 (5.1) |
40–55 years | 88 (31.2) | 224 (33.5) |
>55 years | 188 (66.7) | 411 (61.4) |
Tumor sizeb
| ||
Mean (SD)c, cm | 1.87 (1.0) | 2.1 (1.0) |
Median (range), cm | 1.6 (up to 6.5) | 1.9 (up to 6) |
Tumor grade categoryb,d, N (%) | ||
Grade 1 | 40 (14.2) | 75 (11.2) |
Grade 2 | 155 (55.0) | 323 (48.0) |
Grade 3 | 46 (16.3) | 194 (29.0) |
Not applicable/unknown | 41 (14.5) | 77 (11.5) |
Nodal involvemente, N (%) | ||
Micrometastases | 135 (47.9) | 82 (12.3) |
1 positive node | 101 (35.8) | 338 (50.5) |
2 positive nodes | 38 (13.5) | 160 (23.9) |
3 positive nodes | 8 (2.8) | 89 (13.3) |
Recurrence Score outcomes and clinicopathologic characteristics
Recurrence Score | |||
---|---|---|---|
Low (<18) | Intermediate (18–30) | High (≥31) | |
n = 156 |
n = 108 |
n = 18 | |
All (N = 282) | |||
Age | |||
Median (range), year | 62 (39–87) | 60 (36–78) | 62.5 (38–73) |
Age category, n
| |||
<40 (n = 6) | 2 | 2 | 2 |
40–55 (n = 88) | 49 | 34 | 5 |
>55 (n = 188) | 105 | 72 | 11 |
Tumor sizea, mean (SD), cm | 1.7 (0.8) | 2.0 (1.2) | 2.3 (1.2) |
Tumor grade category, n
| |||
Grade 1 (n = 40) | 34 | 6 | 0 |
Grade 2 (n = 155) | 93 | 55 | 7 |
Grade 3 (n = 46) | 12 | 26 | 8 |
Not applicable/unknown (n = 41) | 17 | 21 | 3 |
Nodal involvement, n
| |||
Micrometastases (n = 135) | 78 | 44 | 13 |
1 positive node (n = 101) | 58 | 40 | 3 |
2 positive nodes (n = 38) | 17 | 20 | 1 |
3 positive nodes (n = 8) | 3 | 4 | 1 |
Recurrence Score outcomes and treatments received (all patients)
Oncotype DX group | Controls | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Recurrence Score | ||||||||||
Lowa (<18) | Intermediatea (18–30) | Higha (≥31) | Allb
| Allb
| ||||||
N = 282 |
N = 669 | |||||||||
n = 156 |
n = 108 |
n = 18 | ||||||||
Treatment | No. | % | No. | % | No. | % | No. | % | No. | % |
Chemotherapy plus endocrine therapy | 11 | 7.1 | 40 | 37.0 | 18 | 100.0 | 69 | 24.5 | 469 | 70.1 |
Endocrine therapy | 145 | 92.9 | 68 | 63.0 | 0 | 0.0 | 213 | 75.5 | 200 | 29.9 |
Recurrence Score outcomes and treatments received: subanalysis by tumor size, grade, and nodal status
Chemotherapy use in the Oncotype DX and control groups: multivariate logistic regression analyses
Effecta
| Odds ratio | 95 % Wald confidence limits |
P value |
---|---|---|---|
Oncotype DX testing (vs. no testing) |
0.16
|
0.11–0.24
|
<0.0001
|
Age | |||
40–55 vs. <40 years | 1.15 | 0.42–3.16 | 0.78 |
>55 vs. <40 years |
0.27
|
0.10–0.72
|
0.0088
|
>55 vs. 40–55 years |
0.24
|
0.16–0.34
|
<0.0001
|
Tumor size | |||
1–2 vs. <1 cm |
0.46
|
0.25–0.83
|
0.0095
|
>2 vs. <1 cm | 0.64 | 0.35–1.15 | 0.14 |
>2 vs. 1–2 cm | 1.40 | 0.98–1.98 | 0.063 |
Tumor grade | |||
Grade 2 vs. 1 |
1.76
|
1.08–2.85
|
0.023
|
Grade 3 vs. 1 |
3.88
|
2.21–6.79
|
<0.0001
|
Grade 3 vs. 2 |
2.21
|
1.47–3.30
|
0.0001
|
Nodal status | |||
1 positive node vs. micrometastases |
1.66
|
1.05–2.63
|
0.029
|
2 positive nodes vs. micrometastases |
1.91
|
1.12–3.24
|
0.017
|
3 positive nodes vs. micrometastases |
7.29
|
3.36–15.84
|
<0.0001
|
2 vs. 1 positive nodes | 1.15 | 0.76–1.75 | 0. 52 |
3 vs. 1 positive nodes |
4.38
|
2.17–8.86
|
<0.0001
|
3 vs. 2 positive nodes |
3.82
|
1.81–8.08
|
0.0004
|
Effecta
| Odds ratio | 95 % Wald confidence limits |
P value | Odds ratio | 95 % Wald confidence limits |
P value |
---|---|---|---|---|---|---|
Patients aged 40–55 years | Patients aged >55 years | |||||
Oncotype DX testing (vs. no testing) |
0.067
|
0.03–0.15
|
<0.0001
|
0.24
|
0.15–0.39
|
<0.0001
|
Tumor size | ||||||
1–2 vs. <1 cm | 0.26 | 0.068–0.97 | 0.046 | 0.56 | 0.28–1.12 | 0.10 |
>2 vs. <1 cm | 0.52 | 0.14–1.94 | 0.33 | 0.73 | 0.36–1.46 | 0.37 |
>2 vs. 1–2 cm | 2.03 | 0.98–4.21 | 0.056 | 1.29 | 0.85–1.97 | 0.23 |
Tumor grade | ||||||
Grade 2 vs. 1 | 2.40 | 0.94–6.12 | 0.067 | 1.50 | 0.84–2.67 | 0.17 |
Grade 3 vs. 1 |
5.08
|
1.58–16.27
|
0.0063
|
3.01
|
1.56–5.81
|
0.001
|
Grade 3 vs. 2 | 2.12 | 0.84–5.32 | 0.11 |
2.02
|
1.27–3.21
|
0.0031
|
Nodal status | ||||||
1 positive node vs. micrometastases | 1.66 | 0.69–3.96 | 0.26 | 1.75 | 0.99–3.11 | 0.055 |
2 positive nodes vs. micrometastases | 1.33 | 0.44–4.04 | 0.61 |
2.18
|
1.15–4.15
|
0.017
|
3 positive nodes vs. micrometastases | 4.19 | 0.70–24.88 | 0.12 |
8.15
|
3.38–19.67
|
<0.0001
|
2 vs. 1 positive nodes | 0.80 | 0.31–2.07 | 0.65 | 1.24 | 0.77–2.00 | 0.37 |
3 vs. 1 positive nodes | 2.53 | 0.46–13.99 | 0.29 |
4.65
|
2.16–10.01
|
<0.0001
|
3 vs. 2 positive nodes | 3.14 | 0.51–19.56 | 0.22 |
3.74
|
1.65–8.45
|
0.0015
|